Mode
Text Size
Log in / Sign up
N/A Completed N=38 Randomized Triple-blind Treatment

Effects of Varenicline on Brain Activity During Nicotine Abstinence

Source: ClinicalTrials.gov NCT00602927 ↗
Enrolled (actual)
38
Serious AEs
0.0%
Results posted
May 2011
Primary outcomePrimary: Percent Change BOLD Signal — 0.48; 0.61 BOLD Signal Change (3-back minus 0-back)

Summary

This project aims to define mechanisms through which varenicline might be an effective smoking cessation medication.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percent Change BOLD Signal
0.48; 0.61 —
SECONDARY
Effect of Varenicline Treatment on Task Performance (N-back Correct Response Time)
692.14; 637.99 —

Eligibility Criteria

Inclusion Criteria

  • Treatment-seeking smokers between the ages of 18 and 65, that smoke at least 10 cigarettes/day for at least the past 6 months
  • Provide a baseline CO (carbon monoxide) reading of >10ppm
  • Provide written informed consent and are fluent, English-speaking
  • Weight of equal to or less than 300 lbs

Exclusion Criteria

Smoking Behavior

  • Use of chewing tobacco, snuff or cigars
  • Current enrollment or plans to enroll in another smoking cessation program in the next 5 months
  • Plan to use other nicotine substitutes or smoking cessation treatments in the next 5 months
  • Provide a baseline CO (carbon monoxide) reading ≤10 ppm

Alcohol/Drug Exclusion Criteria

  • History of substance abuse and/or currently receiving treatment for substance abuse
  • Current alcohol consumption that exceeds 25 standard drinks/week
  • A breath alcohol concentration reading ≥ 0.01 at the H&P (health & physical) screening or either of the lab sessions

Medication Exclusion Criteria

  • Prior use of Chantix
  • Current use or recent discontinuation (within last 14-days) of the following medications:
  • Any form of smoking cessation medication
  • Any form of anti-psychotic medications that includes:
  • antipsychotics,
  • atypical antipsychotics,
  • mood-stabilizers,
  • anti-depressants (tricyclic, SSRI, MAOI),
  • anti-panic agents,
  • anti-obsessive agents,
  • anti-anxiety agents, and
  • stimulants (e.g., Provigil, Ritalin)
  • herbal medications (St. John's Wort)
  • Opioid medication for chronic pain
  • Anti-coagulants
  • Any heart medications
  • Daily medication for asthma

Medical Exclusion Criteria

  • Women who are pregnant, planning a pregnancy, or lactating;
  • History or current diagnosis of psychosis, current major depression, bipolar disorder, ADHD, schizophrenia, or any Axis 1 disorder as identified by the MINI
  • Serious or unstable disease within the past 6 months (heart disease, HIV)
  • Diagnosis of cancer in the past 6 months or if successful treatment for cancer has not ended within the past 6 months
  • History of epilepsy or a seizure disorder
  • History or current diagnosis (last 6-months) of abnormal rhythms and/or tachycardia (>100 beats/minute); history or current diagnosis of COPD (chronic obstructive pulmonary disease), cardiovascular disease (stroke, angina, coronary heart disease), heart attack in the last 6 months, uncontrolled hypertension (SBP>150 or DBP>90)
  • History of kidney and/or liver failure (including transplant)
  • History of head trauma or prior seizure; family history of a seizure disorder, brain (or central nervous system) tumor
  • Use of pacemakers, certain metallic implants, or presence of metal in the eye as contraindicated for MRI (magnetic resonance imaging);
  • Low or borderline intellectual functioning - determined by receiving a score <80 on the Shipley verbal IQ Test
  • Non-English speaking; determined at phone screen
  • History of claustrophobia (contraindicated for MRI) or color blindness (task requires color recognition); self-report at telephone screen
  • Being left-handed
  • Any fore-limb deformity
  • Wearing cochlear implant or bi-lateral hearing aids

General Exclusion

  • Any medical condition or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and/or Study Physician.
  • Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician.
  • Any physical or visual impairment that may prevent the individual from using a computer keyboard or completing any study tasks.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00602927). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search